跳至主要内容
临床试验/NCT01875263
NCT01875263终止3 期

Efficacy of a Short-term Sequential Therapy Versus Intravenous Standard Treatment for Patients With Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.

Fundación Pública Andaluza Progreso y Salud11 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2013年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
1
试验地点
11
主要终点
Reduce the rate of late complications of catheter-related bacteremia by S. aureus methicillin sensitive below 2%.

研究概览

简要总结

Evaluate the efficacy of a sequential regimen of 14 days in patients with catheter-related bacteremia by S. aureus methicillin-susceptible, selected based on a pre-established clinical and microbiological criteria.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients ≥ 18 years with a minimum weight of 40 kg.
  • Microbiological Isolation of S. aureus susceptible to meticillin.
  • Start antibiotic treatment with drugs active against S. aureus within 72 hours from the onset of clinical manifestations.
  • Women of childbearing potential, negative pregnancy test negative serum or urine or statement is not pregnant.
  • Prescription prior treatment must be independent and decoupled patient inclusion in the study, corresponding exclusively to clinical practice.

排除标准

  • Polymicrobial bacteremia.
  • Neutropenic patients.
  • Patients addicted to intravenous drugs.
  • Patients with malignancies with expected survival less than 6 months.
  • Severe allergy to beta-lactams or fluoroquinolones.
  • Creatinine clearance <20ml/min.
  • Need for hemodialysis, peritoneal dialysis or plasmapheresis.
  • Clinical signs of deep infection in the first five days of treatment (mucocutaneous lesions suggestive of IE, embolic events, suppurative thrombophlebitis.
  • Predictors of bacteremia complicated:
  • Positive blood cultures for 48-96 hours of starting treatment antistaphylococcal
  • Clinical Instability
  • Signs of sepsis or persistent fever at day 4 of treatment
  • Existence of valvular or vascular prosthetic joints, vascular catheter not removed within three days
  • Heart disease predisposing to endocarditis.
  • Patients presenting diagnosis concomitant infection by another organism.
  • Pregnant or breast-feeding.
  • Patients with epilepsy.
  • Patients with a history of tendon disorders related to fluoroquinolone administration.
  • Not have signed informed consent.

研究组 & 干预措施

Control

Active Comparator

Cloxacillin 2g / 4 hrs iv 14 days

干预措施: Cloxacillin (Drug)

Experimental

Experimental

Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.

干预措施: Cloxacilin (Drug)

Experimental

Experimental

Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.

干预措施: Levofloxacin (Drug)

结局指标

主要结局

Reduce the rate of late complications of catheter-related bacteremia by S. aureus methicillin sensitive below 2%.

时间窗: 18 months

次要结局

  • Reducing hospital stay associated with the treatment of uncomplicated bacteremia MS S. aureus.(18 months)
  • Reduce the transesophagic echocardiography(18 months)

研究者

发起方
Fundación Pública Andaluza Progreso y Salud
申办方类型
Other
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验